Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib plus letrozole vs letrozole alone in postmenopausal ER+/PgR+/HER2- advanced breast cancer
2008-006252-21Phase 2Completed
- Sponsor
- Wyeth
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bosutinib in breast cancer (2 arms), sponsored by Wyeth. Primary endpoint: Progression-Free Survival. Started Mar 2009; status: completed.
02
Drugs
bosutinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-006252-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006252-21.